Search results for "From ACP Journal Club"
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023
In types 1 and 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA1c at 26 wk
The arrival of once-weekly insulin will undoubtedly be welcomed by patients and clinicians, but the advantages of fewer shots will have to be weighed against less flexibility in dosing of basal insulin, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/07/14/7.htm
14 Jul 2023
In prediabetes, oral vitamin D reduces progression to new-onset diabetes
Other preventive treatments for patients with prediabetes may be more effective than this review found vitamin D to be, but vitamin supplementation has advantages of convenience, tolerability, availability, and cost over other options, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/8.htm
12 May 2023
In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA1c at 26 wk
Weekly insulin injections might be optimal for patients with type 2 diabetes who are already taking weekly glucagon-like peptide 1 receptor agonists and need additional basal insulin, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/08/11/6.htm
11 Aug 2023
Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin
Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/8.htm
13 Jan 2023
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022
In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d
The availability of an app that delivers cognitive behavioral therapy to patients with diabetes could have meaningful clinical effects, but it remains to be seen whether behavior changes are sustained long-term, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/10.htm
13 Jan 2023
In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps
A challenge to wider use of the open-source systems to manage type 1 diabetes (T1DM) is that they are not approved by the FDA and thus require clinicians to be willing to learn from and support their patients, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/01/13/9.htm
13 Jan 2023
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022